mouse anti human cd33  (Novus Biologicals)

Journal: Cell Reports Medicine

Article Title: Identification of cells of leukemic stem cell origin with non-canonical regenerative properties

doi: 10.1016/j.xcrm.2024.101485

Figure Lengend Snippet: RECs demonstrate no stemness capacity and co-localize to CD34 + cells within leukemic tissue (A) Representative flow plot of hCD45 and CD33 expression in BM aspirates from PDXs 8 weeks post intra-femoral injection with RECs (n = 11, N = 3). (B) Bar graph of mean ± SD of CFU frequency (#colonies/cells seeded) of FACS-purified CD74 + /CD68 + cells and bulk AML patient MNCs normalized to average AML patient MNCs. (C) Bar graph of leukemic mutation VAF of FACS-purified CD74 + /CD68 + cells compared with control MNCs. (D) Whole H&E-stained tissue and representative images with and without spot overlays of BM tissue from AML patient 11 and BM donor 4. Scale bar, 100 μM. (E) Spots of CD74 + /CD68 + /CD34 + co-expression overlayed onto whole tissue section of AML BM11, and four representative images each from areas with and without CD74 + /CD68 + /CD34 + co-expression. Scale bars, 50 μM. (F) Xenograft BM sections of engrafted CB and AML, with hCD74 hCD68 hCD34 immunofluorescent labels by MIBI-TOF methodology. Examples of CD74 + /CD68 + cells and CD34 + are highlighted in white. (G) Bar graph of the mean +/- SD distance between CD74+/CD68+ and CD34 + cells in the AML vs. CB xenograft BM (∗∗∗∗p < 0.0001, Student’s t test). See also Figure S5 , Table S1 .

Article Snippet: PE mouse anti-human CD33 , BD Biosciences , Cat#347787; RRID: AB_400350.

Techniques: Expressing, Injection, Purification, Mutagenesis, Staining

Journal: Cell Reports Medicine

Article Title: Identification of cells of leukemic stem cell origin with non-canonical regenerative properties

doi: 10.1016/j.xcrm.2024.101485

Figure Lengend Snippet:

Article Snippet: PE mouse anti-human CD33 , BD Biosciences , Cat#347787; RRID: AB_400350.

Techniques: Recombinant, Selection, Software

Journal: bioRxiv

Article Title: Expansion of human hematopoietic stem cells by inhibiting translation

doi: 10.1101/2023.11.28.568925

Figure Lengend Snippet: A. Limiting dilution analysis (LDA) of human UCB CD34 + cells at day 0 or after 7 days of culture in CRCY+DMSO or CRCY with 4E1RCat (2 µM). Dose of cells injected is based on the number of CD34 + cells on day 0. Chimerism was measured as human CD45 + cells at 20 weeks in bone marrow with engraftment defined as ≥ 0.1% hCD45 + . Data are from 2 distinct LDA/transplant experiments. B. HSC frequency with 95% CI calculated with ELDA software. p = 0.001 for CRCY+4E1RCat compared to fresh cells. No significant difference for CRCY+DMSO compared to Day 0 cells. C-F. The percentage of human T cells (CD3 + cells), B cells (CD19 + cells), myeloid cells (CD33 + cells), and lineage negative (CD34 + CD38 - ) cells is shown for recipients injected with cells from ex vivo cultures corresponding to 5000, 500, 100, 25 CD34 + cells on day 0. G. Scheme for secondary transplantation from primary recipients that had received day 0 cells or cells cultured in CRCY+4E1RCat for 7 days. H. The percentage engraftment of human CD45 + cells in peripheral blood (16 weeks) in secondary recipients. I. The percentage engraftment of human CD45 + cells in the bone marrow (18 weeks) in secondary recipients. J-N. The percentage (log 10 scale) of human lineage negative cells (CD34 + CD38 - ), B cells (CD19 + ), myeloid cells (CD33 + ), megakaryocytes (CD41 + ) and erythroid cells (GlyA + ) in the bone marrow (18 weeks) of secondary recipients. Samples with 0% engraftment are shown at the baseline (with broken y-axes),

Article Snippet: After 18 weeks, bone marrow was collected and analyzed with PE anti-human CD45 antibody (CAT# 368510, Biolegend), APC/Cyanine7 anti-mouse CD45 antibody (CAT# 103116, Biolegend), APC anti-human CD3 antibody (CAT# 317318, Biolegend), BB515 Mouse anti-Human CD33 (CAT# 564588, BD Biosciences), BB700 mouse anti-Human CD19 (CAT# 566396, BD Biosciences), Brilliant Violet 421™ anti-human CD41 antibody (CAT# 303730, Biolegend), BUV395 Mouse anti-Human CD235a antibody (CAT# 563810, BD Biosciences), PE/Cyanine7 anti-human CD34 antibody (CAT# 343616, Biolegend), and Brilliant Violet 711™ anti-human CD38 antibody (CAT# 303528, Biolegend).

Techniques: Injection, Software, Ex Vivo, Transplantation Assay, Cell Culture

Journal: bioRxiv

Article Title: Expansion of human hematopoietic stem cells by inhibiting translation

doi: 10.1101/2023.11.28.568925

Figure Lengend Snippet: The percentage of human CD45 + cells, T cells (CD3 + ), B cells (CD19 + ), myeloid cells (CD33 + ), and CD34 + CD38 - cells in each primary recipient mouse at 20 weeks in bone marrow are represented by a heatmap. Red indicates percentage engraftment (human cells) is > 0.1%. Blue indicates human cell engraftment < 0.1%. White indicates percentage engraftment = 0.1%. Data show results from expansion/transplants using 2 distinct mixed donor UCB samples.

Article Snippet: After 18 weeks, bone marrow was collected and analyzed with PE anti-human CD45 antibody (CAT# 368510, Biolegend), APC/Cyanine7 anti-mouse CD45 antibody (CAT# 103116, Biolegend), APC anti-human CD3 antibody (CAT# 317318, Biolegend), BB515 Mouse anti-Human CD33 (CAT# 564588, BD Biosciences), BB700 mouse anti-Human CD19 (CAT# 566396, BD Biosciences), Brilliant Violet 421™ anti-human CD41 antibody (CAT# 303730, Biolegend), BUV395 Mouse anti-Human CD235a antibody (CAT# 563810, BD Biosciences), PE/Cyanine7 anti-human CD34 antibody (CAT# 343616, Biolegend), and Brilliant Violet 711™ anti-human CD38 antibody (CAT# 303528, Biolegend).

Techniques:

Journal: bioRxiv

Article Title: Expansion of human hematopoietic stem cells by inhibiting translation

doi: 10.1101/2023.11.28.568925

Figure Lengend Snippet: A-E. The percentage of human CD45 + cells, CD34 + CD38 - cells, myeloid cells (CD33 + ), T cells (CD3 + ), and B cells (CD19 + ) at day 29 post-transplant in bone marrow of mice used as donors for secondary transplant. Mice had received either uncultured (Day 0) CD34 + cells or cells cultured in CRCY+4E1RCat for 7 days. F. Table showing percent engraftment of each population in each mouse at 29 weeks.

Article Snippet: After 18 weeks, bone marrow was collected and analyzed with PE anti-human CD45 antibody (CAT# 368510, Biolegend), APC/Cyanine7 anti-mouse CD45 antibody (CAT# 103116, Biolegend), APC anti-human CD3 antibody (CAT# 317318, Biolegend), BB515 Mouse anti-Human CD33 (CAT# 564588, BD Biosciences), BB700 mouse anti-Human CD19 (CAT# 566396, BD Biosciences), Brilliant Violet 421™ anti-human CD41 antibody (CAT# 303730, Biolegend), BUV395 Mouse anti-Human CD235a antibody (CAT# 563810, BD Biosciences), PE/Cyanine7 anti-human CD34 antibody (CAT# 343616, Biolegend), and Brilliant Violet 711™ anti-human CD38 antibody (CAT# 303528, Biolegend).

Techniques: Cell Culture

Journal: bioRxiv

Article Title: Expansion of human hematopoietic stem cells by inhibiting translation

doi: 10.1101/2023.11.28.568925

Figure Lengend Snippet: Bone marrow harvested from primary recipients at 29 weeks was transplanted into conditioned secondary recipients as described in . The percentage of human CD45 + cells was measured in peripheral blood (PB) at 16 weeks. Bone marrow (BM) was harvested at 18 weeks and the percentage of human CD45 + cells T cells (CD3 + ), B cells (CD19 + ), myeloid cells (CD33 + ), megakaryocytic cells (CD41 + ), erythroid cells (GlyA + ) and CD34 + CD38 - cells was measured.

Article Snippet: After 18 weeks, bone marrow was collected and analyzed with PE anti-human CD45 antibody (CAT# 368510, Biolegend), APC/Cyanine7 anti-mouse CD45 antibody (CAT# 103116, Biolegend), APC anti-human CD3 antibody (CAT# 317318, Biolegend), BB515 Mouse anti-Human CD33 (CAT# 564588, BD Biosciences), BB700 mouse anti-Human CD19 (CAT# 566396, BD Biosciences), Brilliant Violet 421™ anti-human CD41 antibody (CAT# 303730, Biolegend), BUV395 Mouse anti-Human CD235a antibody (CAT# 563810, BD Biosciences), PE/Cyanine7 anti-human CD34 antibody (CAT# 343616, Biolegend), and Brilliant Violet 711™ anti-human CD38 antibody (CAT# 303528, Biolegend).

Techniques:

Journal: Cell Reports Medicine

Article Title: Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia

doi: 10.1016/j.xcrm.2023.101108

Figure Lengend Snippet:

Article Snippet: APC mouse anti-human CD33 , BD Pharmingen , Cat#551378; RRID: AB_398502.

Techniques: Recombinant, Purification, Selection, Multiplex Assay, Software